Investing
Top 10 Analyst Upgrades and Downgrades (ABT, ARO, BIIB, CELG, CADC, FACT, HBC, LMNX, EDU, SGI)
Published:
Last Updated:
These are this Friday’s top analyst upgrades, downgrades, and initiations seen from Wall Street morning research calls:
Abbott Laboratories (NYSE: ABT) Cut to Sell at Citigroup.
Aeropostale (NYSE: ARO) Raised to Neutral at Piper Jaffray.
Biogen Idec (NASDAQ: BIIB) Started as Neutral at Piper Jaffray.
Celgene (NASDAQ: CELG) Started as Overweight at Piper Jaffray.
China Advanced Construction Materials (NASDAQ: CADC) Started as Buy at Roth Capital.
Facet Biotech (NASDAQ: FACT) Cut to Market Perform at BMO Capital.
HSBC (NYSE: HBC) Cut to Neutral at Goldman Sachs.
Luminex (NASDAQ: LMNX) Started as Buy at Jefferies.
New Oriental Education (NYSE: EDU) Started as Buy at Deutsche Bank.
Pacific Sunwear of California (NASDAQ: PSUN) Cut to Market Perform at FBR.
Silicon Graphics International (NYSE: SGI) Started as Market Perform at Morgan Keegan.
You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.
JON C. OGG
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
